Pi Therapeutics is a preclinical-stage pharmaceutical company dedicated to the development of protein degradation modulators for the treatment of cancer. PI’s lead drug modulates pathways related to proteostasis, offering a unique approach to the preferential targeting of cancer cells. Preclinical data to date have demonstrated a compelling safety and efficacy profile which is differentiated from approved protein degradation inhibitors. The company, located at the Ness Ziona science park in Israel, was founded in 2015 based on technology in-licensed from Johns Hopkins University and has raised a total of approximately $24M to date.